Riboxin, 200 mg 50 pcs

Riboxin is a derivative (nucleoside) of purine, a precursor of adenosine phosphate ATP. It belongs to the group of drugs that stimulate metabolic processes. It has antihypoxic and antiarrhythmic effects. It increases myocardial energy balance, improves coronary circulation, prevents the consequences of intraoperative renal ischemia. It directly participates in glucose metabolism and promotes metabolism in hypoxia and in the absence of ATP.

Activates pyruvic acid metabolism to ensure normal tissue respiration, and also helps activation of xanthine dehydrogenase. It stimulates the synthesis of nucleotides and enhances the activity of some Krebs cycle enzymes. By penetrating into cells, it has a positive effect on metabolic processes in the myocardium – it increases the force of heart contractions and promotes fuller myocardial relaxation in diastole, resulting in an increase in stroke volume. The mechanism of antiarrhythmic action is not fully understood.

Limits platelet aggregation, activates tissue regeneration (especially myocardium and gastrointestinal mucosa).

Pharmacokinetics

Metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. A small amount is excreted in the urine.

Indications

Complex treatment of myocardial infarction, coronary heart disease, cardiac arrhythmias caused by the use of cardiac glycosides against the background of myocardial dystrophy after infectious diseases.

Liver diseases (hepatitis, cirrhosis, fatty degeneration). Surgeries on an isolated kidney (as a means of pharmacological protection when turning off blood circulation).

Pharmacological effect

Riboxin is a derivative (nucleoside) of purine – a precursor of adenosine tiphosphate ATP. Belongs to the group of drugs that stimulate metabolic processes. Has antihypoxic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, and prevents the consequences of intraoperative renal ischemia. It is directly involved in glucose metabolism and promotes the activation of metabolism under hypoxic conditions and in the absence of ATP.

Activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of some Krebs cycle enzymes. Penetrating into cells, it has a positive effect on metabolic processes in the myocardium – it increases the strength of heart contractions and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in stroke volume. The mechanism of antiarrhythmic action is not completely clear.

Reduces platelet aggregation, activates tissue regeneration (especially the myocardium and gastrointestinal mucosa).

Pharmacokinetics

Metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. A small amount is excreted in the urine.

Active ingredient

Inosine

Composition

active substance: inosine 200 mg;

excipients: microcrystalline cellulose 40.0 mg, sucrose 40.0 mg, potato starch 17.0 mg, povidone (polyvinylpyrrolidone) 10.0 mg, croscarmellose sodium 6.0 mg, magnesium stearate 3.0 mg, purified water 4.0 mg;

Contraindications

Hypersensitivity to the drug, gout, hyperuricemia, pregnancy, lactation, age under 18 years (efficacy and safety have not been established). Use with caution in case of renal failure.

Side Effects

Allergic reactions: skin itching, skin hyperemia (the drug should be discontinued). Rarely: increased concentration of uric acid in the blood, exacerbation of gout (with long-term use).

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C. Keep out of the reach of children.

Shelf life

3 years

Manufacturer

Ozon, Russia